Krystal Biotech Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	4,803	3,499	2,040	1,556	1,182	959	300	108	-
Market Cap Growth	-	71.56%	31.13%	31.55%	23.36%	219.69%	178.41%	-	-
Enterprise Value	4,279	2,975	1,669	1,125	915	768	188	58	-0
PE Ratio	435.26	320.10	-14.57	-22.36	-36.76	-50.22	-27.53	-13.60	-
PS Ratio	94.73	69.02	-	-	-	-	-	-	-
PB Ratio	6.17	4.49	3.91	2.62	4.05	4.72	2.65	2.18	-
P/FCF Ratio	-5803.11	-5803.11	-13.28	-13.38	-28.89	-38.21	-25.67	-26.27	-
P/OCF Ratio	-39.40	-39.40	-20.28	-32.45	-45.33	-51.29	-31.75	-27.69	-
EV/Sales Ratio	84.39	58.68	-	-	-	-	-	-	-
EV/EBITDA Ratio	238.97	166.17	-12.16	-16.99	-30.19	-42.68	-17.50	-12.24	0.07
EV/EBIT Ratio	331.75	230.69	-11.93	-16.53	-28.45	-40.24	-17.27	-12.18	0.07
EV/FCF Ratio	-4933.99	-4933.99	-10.87	-9.68	-22.36	-30.62	-16.10	-14.17	0.06
Debt / Equity Ratio	0.01	0.01	0.02	0.01	0.01	0.02	-	-	6.38
Debt / EBITDA Ratio	0.45	0.45	-0.07	-0.12	-0.13	-0.18	-	-	-1.62
Debt / FCF Ratio	-13.42	-13.42	-0.06	-0.07	-0.10	-0.13	-	-	-1.39
Quick Ratio	17.35	17.35	13.14	17.02	17.56	58.22	43.05	77.49	44.72
Current Ratio	17.77	17.77	13.30	17.18	17.80	58.88	43.39	77.99	50.44
Asset Turnover	0.07	0.07	0	0	0	0	0	0	-
Interest Coverage	-	-	-	-45.63	-	-	-	-1.52	-163.29
Return on Equity (ROE)	1.60%	1.60%	-25.80%	-15.00%	-11.70%	-10.60%	-16.90%	-31.80%	-
Return on Assets (ROA)	1.50%	1.50%	-23.80%	-14.20%	-11.20%	-10.30%	-16.50%	-30.30%	-
Return on Capital (ROIC)	-11.82%	-11.82%	-27.34%	-11.35%	-11.15%	-10.71%	-10.52%	-9.65%	-53.61%
Earnings Yield	0.23%	0.31%	-6.86%	-4.47%	-2.72%	-1.99%	-3.63%	-7.35%	-
FCF Yield	-0.01%	-0.02%	-7.53%	-7.47%	-3.46%	-2.62%	-3.90%	-3.81%	-
Buyback Yield / Dilution	-8.87%	-8.87%	-14.84%	-18.15%	-18.15%	-41.93%	-108.99%	-510.89%	-
Total Shareholder Return	-8.87%	-8.87%	-14.84%	-18.15%	-18.15%	-41.93%	-108.99%	-510.89%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).